ADMA BIOLOGICS INC (ADMA) Stock Price & Overview
NASDAQ:ADMA • US0008991046
The current stock price of ADMA is 15.67 USD. Today ADMA is down by -1.01%. In the past month the price decreased by -3.75%. In the past year, price decreased by -14.98%.
ADMA Key Statistics
- Market Cap
- 3.732B
- P/E
- 26.12
- Fwd P/E
- 16.98
- EPS (TTM)
- 0.60
- Dividend Yield
- N/A
ADMA Stock Performance
ADMA Stock Chart
ADMA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ADMA. When comparing the yearly performance of all stocks, ADMA is a bad performer in the overall market: 83% of all stocks are doing better.
ADMA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ADMA. ADMA scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
ADMA Earnings
On February 25, 2026 ADMA reported an EPS of 0.2 and a revenue of 139.16M. The company beat EPS expectations (5.99% surprise) and missed revenue expectations (-2.13% surprise).
ADMA Forecast & Estimates
9 analysts have analysed ADMA and the average price target is 26.18 USD. This implies a price increase of 67.07% is expected in the next year compared to the current price of 15.67.
For the next year, analysts expect an EPS growth of 53.85% and a revenue growth 24.85% for ADMA
ADMA Groups
Sector & Classification
ADMA Financial Highlights
Over the last trailing twelve months ADMA reported a non-GAAP Earnings per Share(EPS) of 0.6. The EPS increased by 20% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.8% | ||
| ROA | 23.54% | ||
| ROE | 30.78% | ||
| Debt/Equity | 0.15 |
ADMA Ownership
ADMA Latest News, Press Relases and Analysis
ADMA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.34 | 401.392B | ||
| AMGN | AMGEN INC | 16.55 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.52 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.4 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.57 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.95 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.85 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.24 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.18 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADMA
Company Profile
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Company Info
IPO: 2013-10-17
ADMA BIOLOGICS INC
465 State Route 17
Ramsey NEW JERSEY 07446 US
CEO: Adam S. Grossman
Employees: 647
Phone: 12014785552
ADMA BIOLOGICS INC / ADMA FAQ
What does ADMA do?
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
What is the stock price of ADMA BIOLOGICS INC today?
The current stock price of ADMA is 15.67 USD. The price decreased by -1.01% in the last trading session.
Does ADMA BIOLOGICS INC pay dividends?
ADMA does not pay a dividend.
How is the ChartMill rating for ADMA BIOLOGICS INC?
ADMA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the expected growth for ADMA stock?
The Revenue of ADMA BIOLOGICS INC (ADMA) is expected to grow by 24.85% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for ADMA BIOLOGICS INC?
ADMA BIOLOGICS INC (ADMA) has a market capitalization of 3.73B USD. This makes ADMA a Mid Cap stock.
What is the Short Interest ratio of ADMA BIOLOGICS INC (ADMA) stock?
The outstanding short interest for ADMA BIOLOGICS INC (ADMA) is 9.25% of its float.